Risks
4 risks
Risk Intelligence
Hospital occupancy ramp-up risk
View Risks →Sat Kartar Life Limited — Q4 FY26
Sat Kartar Life delivered a strong Q4 FY26 with revenue crossing ₹200 crore (up 23% YoY), EBITDA up 73%, and PAT up 74%.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Sat Kartar Life delivered a strong Q4 FY26 with revenue crossing ₹200 crore (up 23% YoY), EBITDA up 73%, and PAT up 74%. Growth was driven by D2C product expansion, higher ticket sizes (now ₹3,250), and the ramp-up of a new 30-bed hospital in Delhi. Management guided for product revenue of ₹300 crore in FY27 and ₹500 crore in FY28, supported by subsidiary Ajuni Life Sciences, US operations, and AI-driven efficiency gains. A strategic partnership with Gina aims to add 300 beds by FY27 and 1,000 by FY28, with a blended PAT margin target of 18-20% by H1 FY28. Key risk: hospital occupancy ramp-up may be slower than expected, given current utilization below 10% and pending insurance empanelment.
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Ticket Size
₹3,250
+150 YoY
Average order value increased from ₹3,100 at IPO to ₹3,250, driving revenue growth.
Hospital Daily Revenue
₹50,000/day
N/A
Current daily revenue for the 30-bed hospital; break-even target is ₹1 lakh/day.
Subsidiary Revenue Target FY27
₹25-30 crore
+20x YoY
Subsidiaries (Ajuni Life Sciences, Plantommed) contributed ₹1.2 crore in FY26; target for FY27.
US Operations Revenue Target FY27
₹10-15 crore
N/A
US subsidiary expected to start contributing in FY27, pending RBI approval.
Fast read
Guidance and risk preview
Management expects product revenue to reach ₹300 crore in FY27, driven by 25% organic growth, subsidiary ramp-up, and US operations.
Current hospital occupancy is below 10% and break-even is not yet achieved; slower-than-expected ramp-up could delay profitability.
View Risks →